



Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	June 3, 2014  June 15, 2016

**FETZIMA® (lenomilnacipran) extended-release capsules**

**LENGTH OF AUTHORIZATION:** Up to one year

**INITIAL REVIEW CRITERIA (ALL OF THE FOLLOWING MUST BE TRUE):**

- Patient must be  $\geq 18$  years old
- Patient must have a confirmed diagnosis of depression
- Trial and failure with a minimum of two other antidepressant drugs within the past 365 days.
  - One of these two antidepressants must have been in the SNRI class AND
  - Claims history documents a minimum of at least 2 consecutive fills (60 day trial) of the SNRI.

*(Failure can be defined as inefficacy or intolerability, **not** non-compliance)*

**CONTINUATION OF THERAPY:**

- Must have recent claims history (within previous 3 months) of Fetzima

**DOSING & ADMINISTRATION:**

- *Recommended dose:* 40 mg to 120 mg once daily with or without food.
- Initiate dose at 20 mg once daily for 2 days and then increase to 40 mg once daily.
- Based on efficacy and tolerability, increase dose in increments of 40 mg at intervals of 2 or more days.
- The maximum recommended dose is 120 mg once daily
- Dosage Form: 20 mg, 40 mg, 80 mg and 120 mg extended release capsules